Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Label Update Emphasizes Importance of RAS Testing in mCRC

April 7th 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

Challenges, Need for New Therapies Remain in HCC

April 6th 2015

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

Dr. Dawson on Increasing Causes and Unmet Needs in HCC

March 26th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, discusses increasing cause of hepatocellular carcinoma (HCC) and unmet needs related to the disease.

GI Specialist Discusses Hurdles in Targeting Gastric Cancers

March 24th 2015

Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.

Controversies in Clinical Care: Questioning Research

March 23rd 2015

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Targeting Gastric Cancer: Recent Advances Generate Fresh Hopes After Many Frustrations

March 11th 2015

As we enter an era of unprecedented clinical trial activity in gastric cancer, with thousands of patients enrolled or set to be enrolled in large, randomized phase III trials of novel targeted agents, we may finally be on the path to changing the course of this disease.

Tivozanib Improves PFS Versus Bevacizumab in NRP-1 Low mCRC

March 10th 2015

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Dr. Cremolini on Identifying Molecular Markers in mCRC

February 25th 2015

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

FDA Accepts NDA for TAS-102 in mCRC

February 24th 2015

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

Analysis Confirms Safety of Regorafenib in mCRC Among Best Responders

February 14th 2015

Adverse events among patients with metastatic colorectal cancer who responded best to regorafenib in the phase III CORRECT trial were "broadly similar" to the overall study population.

Final Thoughts on Improving Outcomes in CRC

January 30th 2015

Impact of Vitamin D on Colorectal Cancer Outcomes

January 30th 2015

Molecular Profiling in Colorectal Cancer

January 30th 2015

Measuring Therapeutic Response in Colon Cancer

January 30th 2015

Third-Line Regorafenib and TAS-102 in mCRC

January 30th 2015

Second-Line Therapy for Metastatic CRC

January 30th 2015

Postoperative Therapy for Metastatic CRC

January 30th 2015

Treatment Selection in RAS Wild-Type mCRC

January 30th 2015

Communication Strategies for Newly Diagnosed mCRC

January 30th 2015

Expanded RAS Testing Required in CRC

January 30th 2015